JP2018528776A5 - - Google Patents

Download PDF

Info

Publication number
JP2018528776A5
JP2018528776A5 JP2018513633A JP2018513633A JP2018528776A5 JP 2018528776 A5 JP2018528776 A5 JP 2018528776A5 JP 2018513633 A JP2018513633 A JP 2018513633A JP 2018513633 A JP2018513633 A JP 2018513633A JP 2018528776 A5 JP2018528776 A5 JP 2018528776A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
antibody
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018513633A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018528776A (ja
JP7020687B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/051847 external-priority patent/WO2017048902A1/en
Publication of JP2018528776A publication Critical patent/JP2018528776A/ja
Publication of JP2018528776A5 publication Critical patent/JP2018528776A5/ja
Application granted granted Critical
Publication of JP7020687B2 publication Critical patent/JP7020687B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018513633A 2015-09-15 2016-09-15 Ｔ細胞受容体（ｔｃｒ）結合抗体及びその使用 Expired - Fee Related JP7020687B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562218990P 2015-09-15 2015-09-15
US62/218,990 2015-09-15
PCT/US2016/051847 WO2017048902A1 (en) 2015-09-15 2016-09-15 T-cell receptor (tcr)-binding antibodies and uses thereof

Publications (3)

Publication Number Publication Date
JP2018528776A JP2018528776A (ja) 2018-10-04
JP2018528776A5 true JP2018528776A5 (OSRAM) 2019-10-17
JP7020687B2 JP7020687B2 (ja) 2022-02-16

Family

ID=56990993

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018513633A Expired - Fee Related JP7020687B2 (ja) 2015-09-15 2016-09-15 Ｔ細胞受容体（ｔｃｒ）結合抗体及びその使用

Country Status (11)

Country Link
US (2) US10633445B2 (OSRAM)
EP (1) EP3349791A1 (OSRAM)
JP (1) JP7020687B2 (OSRAM)
KR (1) KR20180042449A (OSRAM)
CN (1) CN108430506A (OSRAM)
AU (2) AU2016323153B2 (OSRAM)
CA (1) CA2997673A1 (OSRAM)
HK (1) HK1258218A1 (OSRAM)
IL (1) IL258009B2 (OSRAM)
WO (1) WO2017048902A1 (OSRAM)
ZA (1) ZA202002966B (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2997134B1 (en) 2013-05-14 2020-06-24 Board of Regents, The University of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
MX369513B (es) 2014-02-14 2019-11-11 Univ Texas Receptores de antígenos quiméricos y métodos de realización.
EP3215534B1 (en) 2014-11-05 2020-04-15 Board of Regents, The University of Texas System Chimeric antigen receptors (car) to selectively target protein complexes
JP6947647B2 (ja) 2015-02-24 2021-10-13 ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System 遺伝子改変ｔ細胞の選択方法
EP3268470B1 (en) 2015-03-11 2020-11-18 Board of Regents, The University of Texas System Transposase polypeptides and uses thereof
AU2016323153B2 (en) 2015-09-15 2021-04-22 Board Of Regents, The University Of Texas System T-cell receptor (TCR)-binding antibodies and uses thereof
WO2017075147A1 (en) 2015-10-27 2017-05-04 Board Of Regents, The University Of Texas System Chimeric antigen receptor molecules and uses thereof
CN110753555A (zh) 2017-04-19 2020-02-04 得克萨斯州大学系统董事会 表达工程化抗原受体的免疫细胞
WO2019084427A1 (en) * 2017-10-27 2019-05-02 Kite Pharma, Inc. T-LYMPHOCYTE RECEPTOR ANTIGEN BINDING MOLECULES AND METHODS OF USE THEREOF
EP3755349A4 (en) 2018-02-21 2021-11-17 Board of Regents, The University of Texas System PROCESS FOR ACTIVATION AND EXPANSION OF NATURAL KILLER CELLS AND THEIR USES
US20210283180A1 (en) * 2018-07-06 2021-09-16 The Arizona Board Of Regents On Behalf Of The University Of Arizona Car t cell therapy to target t cell specific cancers
CN109136282A (zh) * 2018-09-30 2019-01-04 北京鼎成肽源生物技术有限公司 一种hafft1细胞的构建方法
CN114360644B (zh) * 2021-12-30 2024-12-17 山东师范大学 T细胞受体与抗原表位的结合预测方法及系统
CN117624340B (zh) * 2024-01-23 2024-04-30 北京臻知医学科技有限责任公司 识别人乙型肝炎病毒（hbv）抗原的t细胞受体（tcr）及其用途
WO2025247325A1 (en) * 2024-05-30 2025-12-04 Hanx Biopharmaceuticals, (Wuhan) Ltd. Antibody-drug conjugates targeting trbv12 and uses thereof

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0069151A4 (en) 1981-01-14 1983-05-16 Michael G Knickerbocker VALVE ASSEMBLY WITH INTEGRATED PLASTIC SPRING.
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
DE3668186D1 (de) 1985-04-01 1990-02-15 Celltech Ltd Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
JPS63212525A (ja) 1987-02-28 1988-09-05 Nissei Plastics Ind Co 型締装置
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
ATE120454T1 (de) 1988-06-14 1995-04-15 Cetus Oncology Corp Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus.
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5223426A (en) * 1988-12-15 1993-06-29 T Cell Sciences, Inc. Monoclonal antibodies reactive with defined regions of the t-cell antigen receptor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
AU641673B2 (en) 1989-06-29 1993-09-30 Medarex, Inc. Bispecific reagents for aids therapy
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
JP3319594B2 (ja) 1990-03-20 2002-09-03 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク 定常領域の代わりに受容体結合性リガンドを有するキメラ抗体
ATE175118T1 (de) 1990-10-05 1999-01-15 Medarex Inc Gezielte immunostimulierung mit bispezifischen stoffen
AU8727291A (en) 1990-10-29 1992-06-11 Cetus Oncology Corporation Bispecific antibodies, method of production, and uses thereof
ATE218889T1 (de) 1990-11-09 2002-06-15 Stephen D Gillies Cytokine immunokonjugate
JP3431140B2 (ja) 1991-04-26 2003-07-28 サーフィス・アクティブ・リミテッド 抗体およびその使用方法
WO1993017715A1 (en) 1992-03-05 1993-09-16 Board Of Regents, The University Of Texas System Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US20020064528A1 (en) 2000-01-28 2002-05-30 Zhenping Zhu Antibodies specific to KDR and uses thereof
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
DE60126130T2 (de) 2000-11-17 2007-10-18 The University Of Rochester In-vitro verfahren zur herstellung und identifizierung von immunglobulin moleküle in eukaryotischen zellen
AU2002327164A1 (en) 2001-01-29 2002-12-09 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
US20030020733A1 (en) 2001-07-24 2003-01-30 Yin Memphis Zhihong Computer display having selective area magnification
CN100360565C (zh) * 2001-12-22 2008-01-09 4-抗体股份公司 制备脊椎动物淋巴细胞和生产结合蛋白的方法
AU2011261161A1 (en) * 2010-06-01 2013-01-10 Ludwig Institute For Cancer Research Limited Antibodies directed to the unprocessed receptor tyrosine kinase c-Met
SG188285A1 (en) 2010-09-02 2013-04-30 Vaccinex Inc Anti-cxcl13 antibodies and methods of using the same
WO2013074916A1 (en) 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
TWI745610B (zh) 2012-11-14 2021-11-11 美商再生元醫藥公司 重組細胞表面捕捉蛋白質
WO2014140368A1 (en) 2013-03-15 2014-09-18 Amgen Research (Munich) Gmbh Antibody constructs for influenza m2 and cd3
EP2997134B1 (en) 2013-05-14 2020-06-24 Board of Regents, The University of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
EP3004168A4 (en) 2013-05-24 2017-03-01 Board of Regents, The University of Texas System Chimeric antigen receptor-targeting monoclonal antibodies
EP3060059A4 (en) 2013-10-25 2017-11-01 Board of Regents, The University of Texas System Polyclonal gamma delta t cells for immunotherapy
MX369513B (es) 2014-02-14 2019-11-11 Univ Texas Receptores de antígenos quiméricos y métodos de realización.
JP2017514471A (ja) 2014-04-23 2017-06-08 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム キメラ抗原受容体（ｃａｒ）並びにその製造及び使用方法
CN106459918A (zh) 2014-04-24 2017-02-22 得克萨斯州大学系统董事会 施加诱导多能干细胞产生过继细胞疗法产品
EP3215534B1 (en) 2014-11-05 2020-04-15 Board of Regents, The University of Texas System Chimeric antigen receptors (car) to selectively target protein complexes
US20170333480A1 (en) 2014-11-05 2017-11-23 Board Of Regents, The University Of Texas System Gene modified immune effector cells and engineered cells for expansion of immune effector cells
JP6947647B2 (ja) 2015-02-24 2021-10-13 ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System 遺伝子改変ｔ細胞の選択方法
EP3268470B1 (en) 2015-03-11 2020-11-18 Board of Regents, The University of Texas System Transposase polypeptides and uses thereof
AU2016323153B2 (en) 2015-09-15 2021-04-22 Board Of Regents, The University Of Texas System T-cell receptor (TCR)-binding antibodies and uses thereof
WO2017075147A1 (en) 2015-10-27 2017-05-04 Board Of Regents, The University Of Texas System Chimeric antigen receptor molecules and uses thereof

Similar Documents

Publication Publication Date Title
JP2018528776A5 (OSRAM)
JP7781243B2 (ja) ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法
US12384850B2 (en) Guidance and navigation control proteins and method of making and using thereof
US11202828B2 (en) Therapeutic SIRP-α antibodies
JP6840682B2 (ja) 多重特異的抗原結合タンパク質
CN107405397B (zh) 抗tim-3抗体
JP2022137054A (ja) ＮＫｐ４６結合タンパク質の可変領域
JP2022550832A (ja) Ｃｄ３を標的とする抗体、二重特異性抗体及びその使用
JP2019500892A5 (OSRAM)
JP2019517773A (ja) 抗ｌａｇ−３抗体
JP2019519208A (ja) 抗ｃｔｌａ−４抗体
JP2018524326A (ja) 多重特異的ｎｋエンゲイジャータンパク質
KR20220061982A (ko) 키메라 항원 수용체 및 키메라 항원 수용체를 발현하는 면역 이펙터 세포
JP2018508215A5 (OSRAM)
JP2015163068A5 (OSRAM)
JP2019513725A5 (OSRAM)
CN104822704A (zh) 针对分化簇3(cd3)的人源化的抗体
JP2019512207A5 (OSRAM)
KR20230058074A (ko) Ilt2에 대한 항체 및 이의 용도
JP2023524238A (ja) 治療用ＳＩＲＰα抗体
CN114901364A (zh) 用于治疗实体癌和血液癌的组合疗法
JP2023538117A (ja) 神経免疫疾患のためのｃｄ３／ｃｄ２５抗体
KR20200041377A (ko) Strep-tag 특이적 결합 단백질 및 그 용도
JP2018529672A5 (OSRAM)
AU2015265578B2 (en) Risk-stratification of B-precursor acute lymphoblastic leukemia patients